SCHEMBL3013030

SCHEMBL3013030

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 3/20 0.43
USP2 O75604 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 3/20 0.43
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TSHR P16473 5/20 0.42
LMNA P02545 4/20 0.42
HTT P42858 3/20 0.42
POLB P06746 2/20 0.42
GAA P10253 1/20 0.42
LPAR1 Q92633 4/20 0.42
LPAR2 Q9HBW0 4/20 0.42
THRB P10828 1/20 0.41
TP53 P04637 1/20 0.41
HSD11B1 P28845 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008465 0.93 SMN1; SMN2 (0.49) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3010517 0.92 TSHR (0.49) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3011545 0.92 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3016087 0.91 LMNA (0.47) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3021348 0.90 MAPT (0.42) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3011139 0.90 VCAM1 (0.48) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3013132 0.90 MEN1 (0.48) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3650575 0.89 TSHR (0.46) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3006628 0.89 HTT (0.47) MEN1KMT2ASMN1; SMN2MAPTUSP2
SCHEMBL3008951 0.87 GBA1 (0.43) MEN1KMT2ASMN1; SMN2MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.